

PROBLEM

Chronic non-healing wounds and excessive scar formation are two of the biggest challenges in wound healing. Effective drugs to address these challenges don't exist yet. The outcome of therapies are not satisfactory and worldwide annual costs exceed \$24 B.

Insufficient ocular capillary blood flow in several eye diseases leads to damaging the eye nerve and ultimately to blindness. This high medical need indications represent currently an \$11 B market with an attractive annual growth of 8%.

SOLUTION

TOPADUR has invented a new type of low molecular weight drugs with dual mode of action. These drugs stimulate capillary blood flow with an unprecedented potency and efficacy, enabling therapeutic interventions of so far untreatable problems of tissue regeneration and inhibition of hypoxia induced damaging. TOP-N53 our first priority development drug increases local blood flow in the wound area and addresses the impaired blood flow, a central problem in non-healing wounds. TOP-N53 has a unique mode of action and an unprecedented efficacy to enable wound healing.

TOP-N44 inhibits excessive scar formation, targeting a huge medical need after burn wounds.

TOP-V122 increases ocular microcirculation and has the potential to become a breakthrough drug preventing blindness.

Wound healing
Angiogenesis
TOP-N53
1st priority



- Diabetic foot ulcers*
- Orphan ulcers*
- Decubitus
- Major surgery (incl. bone)
- Dental surgery

Ocular blood flow
Neuroprotection
TOP-V122; TOP-T5
2nd priority



- Glaucoma*
- dry AMD
- Diabetic Retinopathy

Scar prevention
Anti-fibrotic
TOP-N44
3rd priority



- Burn wounds*
- Skin fibrosis
- Fibrotic lung/eye diseases
- Scleroderma
- Cosmetic surgery

Opportunistic R&D
TOP-M119; TOP-N53;
TOP-V122



- ED - Topical
- Pulmonary Arterial Hypertension*
- Medical Cosmetics
- Alopecia*, hearing loss
- skin aging

COMPANY

After six years of intensive lead finding phase Dr. Reto Naef, together with an experienced pharma team, founded TOPADUR Pharma AG in March 2015. The leadership and board members have more than 150 years of successful pharma experience. The development pipeline is supported by strong IP, with several composition of matter patents filed. The invention of new mode of action drugs resulted also in an attractive out-licensing portfolio outside wound healing indications.

The company has 15 employees, seven major collaborations with leading research groups in Europe and four international CROs.

PRODUCT PORTFOLIO

- TOP-N53 Diabetic foot ulcer wound healing, rare wound healing indications
- TOP-N44 Prevention of excessive scar formation
- TOP-V122, TOP-T5 Glaucoma and ophthalmic indications
- TOP-M119 Hair growth
- TOP-N53 Pulmonary arterial hypertension (inhaled) out-licensing
- TOP-V122 Medical cosmetics out-licensing

GROWTH STRATEGY

TOPADUR is developing TOP-N53, TOP-N44 and TOP-V122 to clinical phase 2a and will be partnering with big pharma companies afterwards. In rare disease indications the company intends to bring the product to the market without partnering. TOPADUR has ongoing research projects in several indications with disturbed microcirculation.

FINANCIALS

- \$0.3 M seed round by founder 2009-2015
- \$2.2 M Series A Q1/2016
- \$6.2 M Series B Q2/2017
- \$4.5 M convertible loan Q3/2018
- Non-diluting funding \$3 M
- submitted grant applications \$2.5M
- **next: Series C1 + C2: \$8-14 M 2020**
- **expected exit: 2022**

NEXT MILESTONES

- TOP-N53 end toxicology Q4/19
- IND Q1/20
- FIH Q1/20

IND: investigational new drug; FIH: first in human; POC: proof of concept

AWARDS

- Young Entrepreneur Award 2019
- Winner ED Dong Sheng Cup 2018
- Winner SEF Award 2018
- Top 100 Swiss Startups 2018
- Winner Venture Leaders China 2018
- Winner Swiss Innovation Challenge 2017
- Top 100 Swiss Startups 2017
- Winner IMD Startup 2016
- CTI label company 2016
- Top 100 Swiss Startups 2016
- Winner Venture Leaders Life Science 2016
- Finalist Swiss Innovation Challenge 2015
- Winners Pitching Battle CEO day 2015

TOPADUR Pharma AG
Grabenstrasse 11A
CH-8952 Schlieren
T +41 44 755 44 66
M + 41 79 204 77 05

info@topadur.com
www.TOPADUR.com